An observational study in Osteo Arthritis Shoulders, Traumatic Arthritis and Rheumatoid Arthritis, sponsored by Smith & Nephew, Inc.. Terminated at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-09.
Sponsored by Smith & Nephew, Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Arthritis, Rheumatoid by Smith & Nephew, Inc. — none open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · Smith & Nephew, Inc..
Among the 13 studies in Arthritis, Rheumatoid by Smith & Nephew, Inc., this one is one of 4 that started in 2017, is one of 8 observational ones, and was the 11th registered.
3,338 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →None of the 13 studies in Arthritis, Rheumatoid by Smith & Nephew, Inc. is open now. The open studies under Arthritis, Rheumatoid, anywhere →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 4 started in 2017.
This study's enrollment of 58 is below the median of 176 across 1,017 observational studies indexed under Arthritis, Rheumatoid.
Median enrollment 97 across the 5 interventional studies, 104 across the 8 observational. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
Smith & Nephew, Inc. is the lead sponsor of 134 studies on the registry; 11 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 10 (91%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Arthritis, Rheumatoid by Smith & Nephew, Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A post market, prospective, non-randomized, multi-center, open-label, clinical study using survivorship as the reference performance goal to study the safety and efficacy of the Titan Modular Shoulder System 2.5 when used for primary shoulder arthroplasty.
Patients with shoulder arthritis requiring primary shoulder joint replacement
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For total shoulder arthroplasty, subjects must meet a, b, or c below:
For shoulder hemiarthroplasty, subjects must meet any of the sub-criteria a - g below:
Exclusion Criteria:
Device: Integra Titan Modular Shoulder System 2.5
Primary Shoulder Joint Replacement
Implant Survivorship
Implant survivorship defined as absence of device removal or revision
Time frame: 2 years
Implant Survivorship
Implant survivorship defined as absence of device removal or revision
Time frame: 1,5 and 10 years
Relative change of Range of Motion (ROM) compared to baseline
Relative change of ROM compared to baseline
Time frame: up to 10 years
Relative change of Constant-Murley Score (CMS) compared to baseline
Relative change of CMS compared to baseline
Time frame: up to 10 years
Relative change of American Shoulder & Elbow Surgeons Score (ASES) compared to baseline
Relative change of ASES compared to baseline
Time frame: up to 10 years
Relative change of Single Assessment Numeric Evaluation (SANE) compared to baseline
Relative change of SANE compared to baseline
Time frame: up to 10 years
Relative change of Simple Shoulder Test (SST) compared to baseline
Relative change of SST compared to baseline
Time frame: up to 10 years
Relative change of Pain compared to baseline
Relative change of Visual Analogue Scale (VAS) Pain compared to baseline
Time frame: up to 10 years
Ran from Aug 2017 to primary completion in Mar 2023, 67 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.